Clinical Trial Update: Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a phase 1/2 study evaluating the combination of imatinib and hydroxyurea for chronic myelogenous leukemia (CML) patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Imatinib (imatinib)

Snippet

Sponsor: University of Leipzig | Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 1, Phase 2 | Status: COMPLETED